ATYR PHARMA INC(ATYR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATYR ATYR PHARMA INC

Trading 09-15 14:09:21 EDT

0.3927

+0.0041

+1.06%

High0.4000	Low0.3750	Vol807.79K
Open0.3940	D1 Closing0.3886	Amplitude6.43%
Mkt Cap38.48M	Tradable Cap37.69M	Total Shares97.99M
T/O310.47K	T/O Rate0.84%	Tradable Shares95.97M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ATYR","market":"US","secType":"STK","nameCN":"ATYR PHARMA INC","latestPrice":0.3927,"timestamp":1789495750939,"preClose":0.3886,"halted":0,"volume":807788,"delay":0,"changeRate":0.010550694801852785,"floatShares":95966000,"shares":97986634,"eps":-0.621383,"marketStatus":"Trading","change":0.0041,"latestTime":"09-15 14:09:21 EDT","open":0.394,"high":0.4,"low":0.375,"amount":310465.20760848,"amplitude":0.064334,"askPrice":0.3939,"askSize":1400,"bidPrice":0.387,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-0.621383,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"listingDate":1430971200000,"exchange":"NASDAQ","adjPreClose":0.3886,"preHourTrading":{"tag":"盘前","latestPrice":0.3875,"preClose":0.3886,"latestTime":"09:27 EDT","volume":10916,"amount":4307.52979368,"timestamp":1789478861487,"change":-0.0011,"changeRate":-0.002831,"amplitude":0.111683},"postHourTrading":{"tag":"盘后","latestPrice":0.3968,"preClose":0.3886,"latestTime":"19:30 EDT","volume":24132,"amount":9593.1655,"timestamp":1789428650594,"change":0.0082,"changeRate":0.021101,"amplitude":0.025476},"volumeRatio":1.014622,"impliedVol":2.372,"impliedVolPercentile":0.7888},"requestUrl":"/m/hq/s/ATYR","defaultTab":"news","newsList":[{"id":"2666571406","title":"aTyr Pharma Announces Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571406","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571406?lang=en_us&edition=fundamental","pubTime":"2026-09-12 04:07","pubTimestamp":1789157246,"startTime":"0","endTime":"0","summary":"aTyr Pharma announces special shareholder meetingaTyr Pharma will hold a special stockholder meeting in San Diego, California on Oct. 16, 2026.Shareholders will vote on authorizing the board to implement a reverse stock split at a ratio from 1-for-10 to 1-for-50.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL8Dd5QH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664691678","title":"aTyr Pharma Expects FDA Response by Mid-September on Efzofitimod Phase 3 Sarcoidosis Protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2664691678","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664691678?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:36","pubTimestamp":1788294988,"startTime":"0","endTime":"0","summary":"aTyr Pharma expects FDA response by mid-September on efzofitimod Phase 3 sarcoidosis protocolaTyr Pharma expects an FDA response by mid-September on its June protocol submission for a planned Phase 3 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL8dv7gk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014021.USD","BCDF","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BN0W2W23.USD","ATYR","LU2095319765.USD","IE00BGHQF748.EUR","BK4588","BK4112","SG9999014039.USD","IE00BKPKM429.USD","NDAQ","IE00BN0W2V16.EUR","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","BK4139","LU2210149790.SGD","BK4585","IE00BQXX3C00.GBP","LU0314104364.USD","SG9999014005.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664286997","title":"aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2664286997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664286997?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:36","pubTimestamp":1788294969,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nTUA8PMY6F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077886","title":"aTyr Pharma Announces Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077886","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077886?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:01","pubTimestamp":1788174076,"startTime":"0","endTime":"0","summary":"aTyr Pharma announces special shareholder meetingaTyr Pharma schedules a special shareholder meeting in San Diego on Oct. 16, 2026.Vote sought to authorize a reverse stock split, with the ratio set by","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDLY73Zz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658193426","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Embecta Corporation (EMBC) and aTyr Pharma (ATYR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658193426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658193426?lang=en_us&edition=fundamental","pubTime":"2026-08-10 22:01","pubTimestamp":1786370462,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Embecta Corporation (EMBC) and aTyr Pharma (ATYR)....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-embecta-corporation-embc-and-atyr-pharma-atyr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-embecta-corporation-embc-and-atyr-pharma-atyr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4139","EMBC","XBI","LABU","LU0029874061.USD","ATYR","HCSG","BK4581","BK4198","LU0128526141.USD","BK4588","BK4585","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626404","title":"ATyr Pharma to Cut 60% of Staff, Bring in New CFO in Restructuring Push","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626404","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626404?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:31","pubTimestamp":1786134660,"startTime":"0","endTime":"0","summary":"ATyr Pharma appointed a new finance chief and said it would lay off around 60% of its staff in an effort to conserve capital and prioritize the development of efzofitimod, its interstitial lung diseas","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ATyr Pharma to Cut 60% of Staff, Bring in New CFO in Restructuring Push","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657266426","title":"aTyr Pharma Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657266426","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657266426?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:20","pubTimestamp":1786134041,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc reports results for the quarter ended June 30 - Earnings SummaryaTyr Pharma IncATYR.OQreported a quarterly adjusted loss of 11 cents per share for the quarter ended June 30, higher tha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4442HF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657062657","title":"aTyr Pharma Q2 Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2657062657","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657062657?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:17","pubTimestamp":1786133859,"startTime":"0","endTime":"0","summary":"aTyr Pharma Q2 net loss narrowsOverviewUS biotech firm posted Q2 net loss of $10.3 mln vs loss of $19.5 mln year agoCompany announced 60% workforce reduction to focus on efzofitimod in ILDEnded Q2 202","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL1N4440Y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","BK4139","BK4532","BK4583","LU1699723380.USD","UTHR","IMRX","ATYR","EBS","BK4539","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657800626","title":"aTyr Pharma Submits Phase 3 Efzofitimod Trial Protocol to FDA for Pulmonary Sarcoidosis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2657800626","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657800626?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:08","pubTimestamp":1786133294,"startTime":"0","endTime":"0","summary":"aTyr Pharma submits Phase 3 efzofitimod trial protocol to FDA for pulmonary sarcoidosis studyaTyr Pharma completed enrollment in its Phase 2 EFZO-CONNECT study of efzofitimod in SSc-ILD; topline resul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL7HzPMm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657625069","title":"aTyr Pharma Q2 EPS $(0.11) Beats $(0.12) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657625069","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657625069?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:02","pubTimestamp":1786132931,"startTime":"0","endTime":"0","summary":"aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 50 percent increase over losses of $(0.22) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61055869/atyr-pharma-q2-eps-0-11-beats-0-12-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"aTyr Pharma Q2 EPS $(0.11) Beats $(0.12) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657756625","title":"aTyr Pharma - Expects $13 Mln Reduction in Annualized Operating Expenses Beginning Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657756625","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657756625?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:01","pubTimestamp":1786132860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA7ZRM8M:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657625758","title":"aTyr Pharma - Announces Workforce Reduction of About 60% to Focus on Efzofitimod Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2657625758","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657625758?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:01","pubTimestamp":1786132860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA7ZRM8M:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657625754","title":"aTyr Pharma - Jill Broadfoot to Step Down as CFO; Brandon Yaras Appointed CFO Effective October 1, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657625754","media":"THOMSON REUTERS","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657625754?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:01","pubTimestamp":1786132860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA7ZRM8M:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657625012","title":"Press Release: aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD","url":"https://stock-news.laohu8.com/highlight/detail?id=2657625012","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657625012?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:01","pubTimestamp":1786132860,"startTime":"0","endTime":"0","summary":"resources to support the efzofitimod program in ILD in anticipation of. comments from the FDA on a protocol submitted for a planned Phase 3 study. in pulmonary sarcoidosis and to complete the Phase 2 EFZO-CONNECT. -- Jill Broadfoot, aTyr's Chief Financial Officer , will step down as. of September 30, 2026, and transition to serve as a consultant t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4555","BK4604","CFO","03160","ATYR","BK4099","BK4139","FVC","LABU","TM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656304816","title":"Ethos Technologies Q2 Revenue Rises 113% on Policy Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2656304816","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656304816?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:19","pubTimestamp":1785788389,"startTime":"0","endTime":"0","summary":"Ethos Technologies Q2 revenue rises 113% on policy growthOverviewUS life insurance tech firm's Q2 revenue grew 113% yr/yr to $190 mlnNet income for Q2 was $19.5 mln; adjusted EBITDA margin reached 19%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL1N440106:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4173","BK4563","ATYR","BK4139","LIFE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656820301","title":"aTyr Pharma Q2 Net Income USD 19.531 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656820301","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656820301?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:05","pubTimestamp":1785787503,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nPLX68GRR2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656375707","title":"aTyr Pharma Inc Expected to Post a Loss of 12 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656375707","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656375707?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:44","pubTimestamp":1785757459,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc <ATYR.OQ> expected to post a loss of12cents a share - Earnings PreviewaTyr Pharma IncATYR.OQATYR.Ois expected to  show no change in quarterly revenue when it reports  results on August","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL8N440124:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656666391","title":"aTyr Pharma - Co and Kyorin Terminate Collaboration Agreement Effective July 30, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2656666391","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656666391?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:48","pubTimestamp":1785530883,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X2NR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656391665","title":"aTyr Pharma - Regains Exclusive Global Rights to Efzofitimod - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2656391665","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656391665?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:48","pubTimestamp":1785530883,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X2NR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655882330","title":"aTyr Pharma Lawsuit: Company Asks Court to Dismiss Investor Securities Claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2655882330","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655882330?lang=en_us&edition=fundamental","pubTime":"2026-07-29 02:56","pubTimestamp":1785265000,"startTime":"0","endTime":"0","summary":"aTyr Pharma (ATYR) and two executives have asked a federal court to dismiss an amended investor lawsuit over statements tied to the company’s efzof...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/atyr-pharma-lawsuit-company-asks-court-to-dismiss-investor-securities-claims?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/atyr-pharma-lawsuit-company-asks-court-to-dismiss-investor-securities-claims?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATYR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atyrpharma.com","stockEarnings":[{"period":"1week","weight":-0.2186},{"period":"1month","weight":-0.3048},{"period":"3month","weight":-0.1322},{"period":"6month","weight":-0.5232},{"period":"1year","weight":-0.9356},{"period":"ytd","weight":-0.5038}],"compareEarnings":[{"period":"1week","weight":-0.0121},{"period":"1month","weight":-0.0199},{"period":"3month","weight":0.0141},{"period":"6month","weight":0.1504},{"period":"1year","weight":0.1574},{"period":"ytd","weight":0.1158}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.727273,"avgChangeRate":0.035951},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.011862},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.068704},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.026181},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.082646},{"month":6,"riseRate":0.583333,"avgChangeRate":-0.008959},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.016959},{"month":8,"riseRate":0.25,"avgChangeRate":-0.046901},{"month":9,"riseRate":0.416667,"avgChangeRate":-0.009374},{"month":10,"riseRate":0.363636,"avgChangeRate":0.029504},{"month":11,"riseRate":0.545455,"avgChangeRate":0.024303},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.061175}],"exchange":"NASDAQ","name":"ATYR PHARMA INC","nameEN":"ATYR PHARMA INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ATYR PHARMA INC(ATYR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ATYR PHARMA INC(ATYR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ATYR PHARMA INC,ATYR,ATYR PHARMA INC股票,ATYR PHARMA INC股票老虎,ATYR PHARMA INC股票老虎国际,ATYR PHARMA INC行情,ATYR PHARMA INC股票行情,ATYR PHARMA INC股价,ATYR PHARMA INC股市,ATYR PHARMA INC股票价格,ATYR PHARMA INC股票交易,ATYR PHARMA INC股票购买,ATYR PHARMA INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ATYR PHARMA INC(ATYR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ATYR PHARMA INC(ATYR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction